Recent translational research: Antiangiogenic therapy for breast cancer - Where do we stand?

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

The central importance of angiogenesis and our understanding of how new blood vessels are formed have led to the development of novel antiangiogenic therapies. Although the number of agents in development has grown exponentially, only one phase III trial in breast cancer has been completed. In that study the addition of bevacizumab to capecitabine did not extend the progression-free survival of patients with refractory disease as compared with capecitabine monotherapy. Early enthusiasm for antiangiogenic therapy must give way to clinical reality. Our challenge now is to exploit better the activity of antiangiogenic agents seen in the early clinical studies.

Original languageEnglish (US)
Pages (from-to)128-132
Number of pages5
JournalBreast Cancer Research
Volume6
Issue number3
DOIs
StatePublished - May 1 2004

Keywords

  • Angiogenesis
  • Breast cancer
  • Matrix metalloproteinase inhibitor
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Recent translational research: Antiangiogenic therapy for breast cancer - Where do we stand?'. Together they form a unique fingerprint.

  • Cite this